Anabolic steroidAndrogenProhormoneDHT-derived

1-Androstenediol

Also known as 1-Androstene-3b,17b-diol · 1-AD (diol)

Written by enwyReviewed 5 Aug 20262 sources0 comments

The diol form of the 1-testosterone pathway, converting to 1-testosterone (dihydroboldenone) via one fewer oxidation step than 1-DHEA. A non-aromatising, dry-gain prohormone with the same DHT-type side effect and suppression profile. DASCA-scheduled in the US.

01 Overview

1-Androstenediol (1-androstene-3-beta,17-beta-diol) is closely related to 1-DHEA but is already reduced at C17, so it converts to 1-testosterone with one enzymatic step. Downstream it delivers the same active androgen, dihydroboldenone, giving lean, non-estrogenic gains.

Like the rest of the 1-ene series, it has no controlled human trials; its properties are extrapolated from 1-testosterone and anecdotal use. It is a scheduled anabolic steroid under DASCA.

02 Mechanism

Oxidised by 17-beta-HSD to 1-testosterone (dihydroboldenone), a non-aromatising androgen resistant to 5-alpha reduction.

03 Dosing

Tier	Dose	Route	Notes
Community-typical	100–300 mg/day	Oral	Reported prohormone dosing; not medically validated.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Lean, dry mass gainsReported to give the same dry lean gains as 1-DHEA with slightly more efficient conversion.	Modest lean gain (reported)	Anecdotal
No aromatisationEnd product does not convert to estrogen.	Non-aromatising	Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
LethargyFatigue similar to other 1-testosterone precursors.	Moderate	Commonly reported	Anecdotal
HPTA suppressionStrong suppression of natural testosterone.	Moderate	Near-universal	Anecdotal

06 Legal status

United States

Schedule III controlled (DASCA 2014)

Anabolic steroid under the Designer Anabolic Steroid Control Act. · as of Jan 2026

07 References

1-Testosterone (dihydroboldenone) pharmacologySteroids, review

Designer Anabolic Steroid Control Act of 2014US Public Law 113-260

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.